Dynogen Pharmaceuticals, Inc. Files for Bankruptcy
2/25/2009 8:06:27 AM
More...
|
Dynogen Pharmaceuticals, Inc. Presents Results of Its Positive Phase 2 IBS-d Study with DDP225
5/20/2008 6:08:12 AM
More...
|
Dynogen Pharmaceuticals, Inc. to Present Positive Clinical Data for DDP225 and DDP733
4/30/2008 6:35:17 AM
More...
|
Apex Bioventures (PEX) and Dynogen Pharmaceuticals, Inc. Mutually Terminate Merger Agreement
4/17/2008 9:54:46 AM
More...
|
Apex Bioventures (PEX) and Dynogen Pharmaceuticals, Inc. Announce Definitive Merger Agreement
2/6/2008 8:51:45 AM
More...
|
Dynogen Pharmaceuticals, Inc. Expands DDP225 Patent Estate
1/16/2008 8:30:21 AM
More...
|
Dynogen Pharmaceuticals, Inc. Announces Positive Results in Phase 2 IBS-d Study
12/17/2007 9:03:37 AM
More...
|
Dynogen Pharmaceuticals, Inc.'s Prokinetic Drug, DDP733, Enters Phase 2b for Irritable Bowel Syndrome with Constipation
11/8/2007 12:14:16 PM
More...
|
Dynogen Pharmaceuticals, Inc.'s Prokinetic Drug, DDP733, Enters Phase 2b for Irritable Bowel Syndrome with Constipation
11/8/2007 10:02:16 AM
More...
|
Dynogen Pharmaceuticals, Inc.'s Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study
10/15/2007 11:10:17 AM
More...
|
|